ReviewTranslational neurodegeneration2017
Disease modification and Neuroprotection in neurodegenerative disorders.
Review in Translational neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- "Time Saved" Calculations to Improve Decision-Making in Progressive Disease Studies.The journal of prevention of Alzheimer's disease · 2024Trial
- Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.Muscle & nerve · 2021Trial
- Article
- Review
- Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer's Disease.Molecules (Basel, Switzerland) · 2026Review
- Cellular and Molecular Mechanisms of Neuroprotection in Deep Brain Stimulation for Parkinson's Disease.Biomedicines · 2025Review
- Coenzyme QMetabolic brain disease · 2025Article
- Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Sinomenine Modifies Parkinson's Disease Through Nrf2 Activation.Neurochemical research · 2025Article
- Healthcare Complexities in Neurodegenerative Proteinopathies: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Potential of Quercetin as a Promising Therapeutic Agent Against Type 2 Diabetes.Molecules (Basel, Switzerland) · 2025Review
- Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises.Stem cell research & therapy · 2025Review
- Artemisinin Stimulates Neuronal Cell Viability and Possess a Neuroprotective Effect In Vitro.Molecules (Basel, Switzerland) · 2025Article
- Glycosylation in aging and neurodegenerative diseases.Acta biochimica et biophysica Sinica · 2024Review
- Advancing precision medicine therapeutics for Parkinson's utilizing a shared quantitative systems pharmacology model and framework.Frontiers in systems biology · 2024Article
- Pharmacotherapy for Disease Modification in Early Parkinson's Disease: How Early Should We Be?Journal of Parkinson's disease · 2024Review
- The Lysine Demethylase KDM7A Regulates Immediate Early Genes in Neurons.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics.Molecules (Basel, Switzerland) · 2023Review
- Disease modification in inflammatory skin disorders: opportunities and challenges.Nature reviews. Drug discovery · 2023Review
- Quinones as Neuroprotective Agents.Antioxidants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundDisease modifying therapies (DMTs) are urgently needed for neurodegenerative diseases (NDD) such as Alzheimer's disease (AD) and many other disorders characterized by protein aggregation and neurodegeneration. Despite advances in understanding the neurobiology of NDD, there are no approved DMTs. DISCUSSION: Defining disease-modification is critical to drug-development programs. A DMT is an intervention that produces an enduring change in the trajectory of clinical decline of an NDD by impacting the disease processes leading to nerve cell death. A DMT is neuroprotective, and neuroprotection will result in disease modification. Disease modification can be demonstrated in clinical trials by a drug-placebo difference in clinical outcomes supported by a drug-placebo difference on biomarkers reflective of the fundamental pathophysiology of the NDD. Alternatively, disease modification can be supported by findings on a staggered start or delayed withdrawal clinical trial design. Collecting multiple biomarkers is necessary to support a comprehensive view of disease modification.
conclusionDisease modification is established by demonstrating an enduring change in the clinical trajectory of an NDD based on intervention in the fundamental pathophysiology of the disease leading to nerve cell death. Supporting data are collected in clinical trials. Effectively defining a DMT will assist in NDD drug development programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.